Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 213,259 | 258,535 | 187,633 | 220,553 | 177,566 |
| Cost of Goods | 35,627 | 37,664 | 32,663 | 38,755 | 31,062 |
| Gross Profit | 177,632 | 220,871 | 154,970 | 181,798 | 146,504 |
| Operating Expenses | 324,991 | 416,096 | 337,310 | 328,713 | 332,820 |
| Operating Income | -146,732 | -194,561 | -181,677 | -146,160 | -186,254 |
| Interest Expense | 42,362 | 36,816 | 40,274 | 33,416 | 32,515 |
| Other Income | -50,262 | -28,925 | 17,715 | -8,755 | 19,494 |
| Pre-tax Income | -239,356 | -260,302 | -204,236 | -188,331 | -199,275 |
| Income Tax | 985 | -1,842 | 278 | 1,228 | 1,016 |
| Net Income Continuous | -240,341 | -258,460 | -204,514 | -189,559 | -200,291 |
| Net Income | $-240,341 | $-258,460 | $-204,514 | $-189,559 | $-200,291 |
| EPS Basic Total Ops | -2.00 | -2.16 | -1.72 | -1.61 | -1.71 |
| EPS Basic Continuous Ops | -2.00 | -2.16 | -1.72 | -1.61 | -1.71 |
| EPS Diluted Total Ops | -2.00 | -2.16 | -1.72 | -1.61 | -1.71 |
| EPS Diluted Continuous Ops | -2.00 | -2.16 | -1.72 | -1.61 | -1.71 |
| EBITDA(a) | $-126,954 | $-173,110 | $-158,457 | $-123,999 | $-163,392 |